“Carcinoma-in-situ” or “CIS” shall mean a histologically proven, localised pre-invasion lesion where cancer cells have not yet penetrated the basement membrane or invaded (in the sense of infiltrating and/or actively destroying) the surrounding tissues or stroma in any one of the following covered organ groups, and subject to any classification stated:

(a) breast, where the tumour is classified as Tis according to the TNM Staging method;

(b) uterus, vagina, vulva or fallopian tubes where the tumour is classified as Tis according to the TNM Staging method or FIGO Stage 0;

(c) cervix uteri, classified as cervical intraepithelial neoplasia grade III (CIN III) or as Tis according to the TNM Staging method or FIGO* Stage 0;

(d) ovary – include borderline ovarian tumours with intact capsule, no tumour on the ovarian surface, classified as T1aN0M0 (TNM Staging) or FIGO 1A;

(e) Colon and rectum;

(f) Penis;

(g) Testis;

(h) Lung;

(i) Liver;

(j) Stomach and esophagus;

(k) Urinary Bladder – Tis or Ta according to the TNM Staging method; or

(l) Nasopharynx.

For purposes of this Policy, Carcinoma-in-situ must be confirmed by a biopsy.